InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 28 April 2022

MK-4280-003: This phase I/II trial is evaluating an immunotherapy combination (MK-4280 and Pembrolizumab) in patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell LymphomaA Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Clinical summary

Summary

This is a non-randomised trial, including Part A (dose escalation) and Part B (dose expansion) treatment phases. In Part A, patients will be assigned to receive a standard (200mg) dose of Pembrolizumab followed by varying doses (A, B or C) of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. In Part B, patients will be assigned to groups based on their diagnosis. All patients will receive the standard dose (200mg) of Pembrolizumab followed by the recommended phase II dose of MK-4280 by infusion on Day 1 of each 3-week cycle for up to 35 cycles.

Conditions

This trial is treating patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma.

Cancer

Blood Cancers Blood

Age

People18+

Phase

I/II

Trial Acronym

MK-4280-003

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Merck

Scientific Title

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Eligibility

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.